Literature DB >> 10895262

Adhesive receptors on malaria-parasitized red cells.

D I Baruch1.   

Abstract

Antigenic variation, rosetting and cytoadhesion are key determinants in the survival and virulence of the malaria parasite Plasmodium falciparum. These properties reside in a multigene protein family called P. falciparum erythrocyte membrane protein I (PfEMPI), encoded by the large and diverse var gene family. PfEMPI plays a central role in the biology of P. falciparum and its interaction with the human host. The molecular mechanism and the domains involved in cytoadherence, rosetting and antigenic variation are beginning to unfold. Domains mediating rosetting and adhesion to several key host receptors have already been identified. Understanding the role of PfEMPI in the pathogenesis and survival of malaria parasites is the key for the development of anti-adhesion vaccines and therapeutics to reduce the mortality and morbidity of P. falciparum infections.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10895262     DOI: 10.1053/beha.1999.0051

Source DB:  PubMed          Journal:  Baillieres Best Pract Res Clin Haematol


  10 in total

1.  Immunization of Aotus monkeys with a functional domain of the Plasmodium falciparum variant antigen induces protection against a lethal parasite line.

Authors:  Dror I Baruch; Benoit Gamain; John W Barnwell; JoAnn S Sullivan; Anthony Stowers; G Gale Galland; Louis H Miller; William E Collins
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

2.  Advances and challenges in malaria vaccine development.

Authors:  Ruobing Wang; Joseph D Smith; Stefan H I Kappe
Journal:  Expert Rev Mol Med       Date:  2009-12-16       Impact factor: 5.600

Review 3.  Genetics of antigenic variation in Plasmodium falciparum.

Authors:  Ron Dzikowski; Kirk W Deitsch
Journal:  Curr Genet       Date:  2009-02-26       Impact factor: 3.886

4.  Fibrinogen binding to intercellular adhesion molecule 1: implications for Plasmodium falciparum adhesion.

Authors:  Carolyn Gray; Alister Craig
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

5.  Temporal expression and localization patterns of variant surface antigens in clinical Plasmodium falciparum isolates during erythrocyte schizogony.

Authors:  Anna Bachmann; Michaela Petter; Ann-Kathrin Tilly; Laura Biller; Karin A Uliczka; Michael F Duffy; Egbert Tannich; Iris Bruchhaus
Journal:  PLoS One       Date:  2012-11-15       Impact factor: 3.240

6.  Pregnancy-associated malaria and the prospects for syndrome-specific antimalaria vaccines.

Authors:  Joseph D Smith; Kirk W Deitsch
Journal:  J Exp Med       Date:  2004-11-01       Impact factor: 14.307

7.  Parasite accumulation in placenta of non-immune baboons during Plasmodium knowlesi infection.

Authors:  Faith I Onditi; Onkoba W Nyamongo; Charles O Omwandho; Naomi W Maina; Fredrick Maloba; Idle O Farah; Christopher L King; Julie M Moore; Hastings S Ozwara
Journal:  Malar J       Date:  2015-03-18       Impact factor: 2.979

8.  High throughput functional assays of the variant antigen PfEMP1 reveal a single domain in the 3D7 Plasmodium falciparum genome that binds ICAM1 with high affinity and is targeted by naturally acquired neutralizing antibodies.

Authors:  Andrew V Oleinikov; Emily Amos; Isaac Tyler Frye; Eddie Rossnagle; Theonest K Mutabingwa; Michal Fried; Patrick E Duffy
Journal:  PLoS Pathog       Date:  2009-04-17       Impact factor: 6.823

9.  Telomere components as potential therapeutic targets for treating microbial pathogen infections.

Authors:  Bibo Li
Journal:  Front Oncol       Date:  2012-11-01       Impact factor: 6.244

10.  Integrin αDβ2 influences cerebral edema, leukocyte accumulation and neurologic outcomes in experimental severe malaria.

Authors:  Isaclaudia G de Azevedo-Quintanilha; Adriana Vieira-de-Abreu; André C Ferreira; Patricia A Reis; Tathiany I Silva; Danielle de O Nascimento; Robert A Campbell; Vanessa Estato; Andrew S Weyrich; Patrícia T Bozza; Guy A Zimmerman; Hugo C Castro-Faria-Neto
Journal:  PLoS One       Date:  2019-12-23       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.